Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Ulcerative Colitis in Children Clinical Presentation

  • Author: Judith R Kelsen, MD; Chief Editor: Carmen Cuffari, MD  more...
 
Updated: Nov 19, 2015
 

History

Ulcerative colitis (UC) is a diffuse mucosal inflammation limited to the colon that affects the rectum; it may extend proximally in a symmetric uninterrupted pattern involving only some of or the entire large intestine. The most common presenting symptoms are rectal bleeding, diarrhea, and abdominal pain. Many patterns of presentation occur in the pediatric age group.

Mild disease is observed in 50-60% of patients. This presentation involves insidious onset of diarrhea, later associated with hematochezia. No systemic findings of fever, weight loss, or hypoalbuminemia are observed. Mild UC is typically confined to the distal colon and responds well to therapy.

Moderate disease is observed in 30% of patients and is characterized by bloody diarrhea, cramps, urgency to defecate, and abdominal tenderness. Associated systemic findings, such as anorexia, weight loss, low-grade fever, and mild anemia, are present.

Severe disease occurs in approximately 10% of patients. This presentation involves more than 6 bloody stools per day, abdominal tenderness, fever, anemia, leukocytosis, and hypoalbuminemia. Patients with severe colitis may experience life-threatening complications, including severe hemorrhage, toxic megacolon, or intestinal perforation.

Less than 5% of children with UC present with predominantly extraintestinal manifestations, such as growth failure, arthropathy, skin manifestations, or liver disease.

A clinical scoring system known as the Pediatric Ulcerative Colitis Activity Index (PUCAI) has been developed and validated.[1] The PUCAI may be used to determine when it is necessary to escalate therapy in fulminant colitis. It is also used to assess disease activity in clinical trials involving pediatric patients with UC.

For more information about the general clinical approach to UC, see Ulcerative Colitis.

Next

Physical Examination

The findings on physical examination in ulcerative colitis (UC) vary with extent, duration, and severity of the disease. In addition to abdominal signs, many extraintestinal manifestations of UC may become evident during physical examination.

Vital signs may indicate fever. Tachycardia may represent anemia or hypovolemia. Tachypnea may be present because of abdominal splinting or as a compensatory mechanism for acidosis in cases of severe dehydration.

Comparison with growth charts may reveal delayed growth. Cushingoid appearance is indicative of steroid use, usually over a long period. The patient may appear toxic in cases of fulminant disease. Long-standing and severe disease may cause signs of malnutrition, such as muscle wasting.

Abdominal examination findings may be normal, but abdominal tenderness is likely. Voluntary or involuntary guarding may be present. Bowel sounds may be normal, hyperactive, or hypoactive; rushes or high-pitched tinkling may be found in cases of obstruction.

Rebound tenderness indicates severe disease and possible perforation. A palpable mass may indicate obstruction or megacolon. An enlarged spleen may be indicative of portal hypertension from associated autoimmune hepatitis or primary sclerosing cholangitis. Long-standing disease can be associated with colonic stricture and evidence for bowel obstruction.

Skin examination may reveal pallor in cases of anemia, decreased skin turgor in cases of dehydration, and jaundice, caput medusae, or spider angiomata when associated liver involvement is present. Erythema nodosum may be evident on extensor surfaces (more common in Crohn disease [CD] than UC); pyoderma gangrenosum affects approximately 1% of UC patients.

Patients with episcleritis can present with a painful erythematous eye. Cataracts may occur in patients with significant steroid history. Scleral icterus may be indicative of liver disease.

Joint pain (arthralgia) is a common finding in inflammatory bowel disease, although swollen or red joints (arthritis) occur less frequently. The large peripheral joints, such as the knees, ankles, wrists, and elbows, are most commonly involved, but any joint can be involved. Approximately 1% of UC patients develop ankylosing spondylitis; most of these patients test positive for human leukocyte antigen (HLA) type B27.

Unlike what is seen in some CD patients, perianal examination in UC patients should not reveal any evidence of fistulae or abscesses; chronic diarrhea may lead to perianal erythema, fissuring, or hemorrhoids, however.

Sexual development may be delayed in patients with UC, but this finding is more common in patients with CD.

Previous
 
 
Contributor Information and Disclosures
Author

Judith R Kelsen, MD Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine; Attending Physician, Division of Gastroenterology, Hepatology and Nutrition, The Children’s Hospital of Philadelphia

Judith R Kelsen, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Study of Liver Diseases, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Nothing to disclose.

Coauthor(s)

Petar Mamula, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine

Petar Mamula, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Gastrointestinal Endoscopy, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, Royal College of Physicians and Surgeons of Canada

Disclosure: Received honoraria from Prometheus Laboratories for speaking and teaching; Received honoraria from Abbott Nutritionals for speaking and teaching.

Acknowledgements

Robert Baldassano, MD, Director, Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia; Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Pennsylvania School of Medicine

Robert Baldassano, MD is a member of the following medical societies:Alpha Omega Alpha, American Academy of Pediatrics, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Abbott Inc, Consulting fee, Consulting

Liz D Dancel, MD Intern, Department of Pediatrics, Greenville Hospital System University Medical Center

Disclosure: Nothing to disclose.

Jonathan Markowitz, MD Assistant Professor, Department of Pediatrics, Inpatient Gastroenterology, Division of Gastroenterology and Nutrition, University of Pennsylvania School of Medicine; Director, The Children's Hospital of Philadelphia.

Jonathan Markowitz is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

David A Piccoli, MD Chief of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine

David A Piccoli, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Jorge H Vargas, MD Professor of Pediatrics and Clinical Professor of Pediatric Gastroenterology, University of California, Los Angeles, David Geffen School of Medicine; Consulting Physician, Department of Pediatrics, University of California at Los Angeles Health System

Jorge H Vargas, MD is a member of the following medical societies: American Liver Foundation, American Society for Gastrointestinal Endoscopy, American Society for Parenteral and Enteral Nutrition, Latin American Society of Pediatric Gastroenterology, Hepatology & Nutrition, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007 Aug. 133(2):423-32. [Medline].

  2. Deutsch DE, Olson AD. Colonoscopy or sigmoidoscopy as the initial evaluation of pediatric patients with colitis: a survey of physician behavior and a cost analysis. J Pediatr Gastroenterol Nutr. 1997 Jul. 25(1):26-31. [Medline].

  3. Vasiliauskas E. Serum immune markers in inflammatory bowel disease. Gastroenterology and Endoscopy News. [Full Text].

  4. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):730-4. [Medline].

  5. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):758-65. [Medline].

  6. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999 Apr. 134(4):447-52. [Medline].

  7. Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr. 26(4):386-92. [Medline].

  8. Eliakim R, Fischer D, Suissa A, et al. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease. Eur J Gastroenterol Hepatol. 2003 Apr. 15(4):363-7. [Medline].

  9. Fell JM, Muhammed R, Spray C, Crook K, Russell RK, BSPGHAN IBD working group. Management of ulcerative colitis. Arch Dis Child. 2015 Nov 9. [Medline].

  10. Kam L. Ulcerative colitis in young adults. Complexities of diagnosis and management. Postgrad Med. 1998 Jan. 103(1):45-9, 53-6, 59. [Medline].

  11. Sarigol S, Wyllie R, Gramlich T, Alexander F, Fazio V, Kay M, et al. Incidence of dysplasia in pelvic pouches in pediatric patients after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999 Apr. 28(4):429-34. [Medline].

  12. Asacol (mesalamine) [package insert]. Rockaway, NJ: Warner Chilcott. 2013. Available at [Full Text].

  13. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009 Feb. 104(2):437-43. [Medline].

  14. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007 Sep. 45(3):306-11. [Medline].

  15. Wiernicka A, Szymanska S, Cielecka-Kuszyk J, Dadalski M, Kierkus J. Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol. 2015 Oct 7. 21 (37):10654-61. [Medline].

  16. Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002 Mar. 34(3):307-11. [Medline].

  17. Prato AP, Pio L, Leonelli L, Pistorio A, Crocco M, Arrigo S, et al. Morbidity and Risk Factors of Laparoscopic Assisted Ileostomies in Children with Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2015 Oct 30. [Medline].

  18. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005 Mar. 11(3):213-8. [Medline].

  19. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1999 Jun. 28(2):371-90, viii-ix. [Medline].

  20. [Guideline] Cohen JL, Strong SA, Hyman NH, Buie WD, Dunn GD, Ko CY, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2005 Nov. 48(11):1997-2009. [Medline].

 
Previous
Next
 
Ulcerative colitis. Specimen from colectomy reveals diffusely hemorrhagic granular mucosa in a continuous distribution.
Histological section: diffuse inflammatory process, limited to mucosa and superficial portion of the submucosa (full thickness biopsy,staining, magnification).
Histological section: diffuse inflammatory process, limited to mucosa and superficial portion of the submucosa (full thickness biopsy,staining, magnification).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.